Genmab — December 2020
-
Tror jeg sælger min spekulative portion i 2500-2600 områden inden weekenden https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/88935_Genmab_e.JPG
-
Så må vi jo se om den kommer derop;-)
-
”De bispecifikke antistoffer repræsenterer en ny immunterapi-æra. I lymfomer ser det rigtig lovende ud, og inden for myelomatose ser vi også gode takter. Det er et princip, jeg har stor tiltro til. Og som jeg forudser kommer til at udkonkurrere CAR-T i en række hæmatologiske sygdomme på sigt,” siger Torben Plesner. https://haematologisktidsskrift.dk/sygdomme/myeloma/776-ny-generation-af-immunterapier-saetter-dagsorden-inden-for-myelomatose.html
-
Multiple Myeloma ~ #ASH20Top10 table update, Talquetamab still in the lead as product abstract https://twitter.com/mtmdphd/status/1333805170757656576
-
Well, hope not Horizon think Genmab has to pay a share of the royalties to HALO
-
God morgen.
-
God morgen
-
Genmab Investor Presentation - December 2020 https://ir.genmab.com/download-library#content
-
Watch this quick video from President and Chief Executive Officer Jan G. J. van de Winkel, Ph.D., to learn more about Genmab and why we put a premium on investing in people. - https://www.genmab.com/careers/ - middle of the page
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind